Phase 1 Trial of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the maximum tolerated dose (MTD) as assessed by measuring dose limiting toxicities (DLT) at each dosing level
From initial dose to the end of three cycles of treatment at each dosing level. Each cycle is 28 days, so approximately 91 days
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
CA180-182
NCT00872976
May 2009
December 2011
Name | Location |
---|---|
Local Institution | Bronx, New York |
Local Institution | Cincinnati, Ohio |
Local Institution | Chattanooga, Tennessee |